Form 4 Filing for ACADIA PHARMACEUTICALS INC

Mark C. Schneyer, EVP, Chief Financial Officer of ACADIA PHARMACEUTICALS INC, reported transactions on April 5th and 7th, 2026. On April 5th, 5,276 Restricted Stock Units were acquired and disposed of, with each unit representing a contingent right to one share of common stock. This transaction was related to the vesting of these units. Additionally, 5,276 shares of Common Stock were acquired with a price of $0.00, resulting in 65,545 shares held post-transaction. On April 7th, 2,709 shares of Common Stock were disposed of at a price of $22.20 per share, leaving 62,836 shares. The mandatory sales were made to cover withholding taxes and tax-related items, intended to comply with Rule 10b5-1(c)(1)(i)(B).